Prothena Biosciences today engaged FLG Partners as interim CFO and to effect the spinout of the company from Elan Pharmaceuticals (NYSE:ELN). FLG Partner: Bern Whitney.
Recent News
Saluda Medical Announces Closing of $100 Million Financing
MINNEAPOLIS, MN — January 10, 2025 (PR Newswire) Saluda Medical, Inc., a commercial-stage medical device company focused on development treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform, today announced the closing of a $100 million financing. FLG Managing Partner Laureen DeBuono assisted as Board of Directors…Read More
Read More
Testimonials
“BrightSource is a complex environment for a variety of reasons: innovative technology, differing objectives among investors, global operations, not quite commercial status – among others. Our FLG partner, Doug Lehrmann, stepped in initially to our CFO slot under a “we need you now” scenario. He quickly sized up the situation, became a respected and trusted member of our Executive Committee and provided quick actions along a variety of fronts that streamlined operations and stabilized the Company. I then asked Doug to move to a newly created COO slot so that I could promote a high potential internal resource to CFO; Doug made the move seamlessly and was invaluable to me in taking on specific tasks that crossed multiple functional responsibilities. BrightSource is a now on path that we believe best positions it for success. Without Doug’s help, I’m not sure we would have the opportunity – for sure full of challenges, but a real chance – that we now have in front of us. Thanks for helping getting Doug to us, and we wish him and FLG much success in the future.”
David Ramm, Chairman and CEO, BrightSourceRead More